Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 287-298 , April 2008

Comparison of the pharmacokinetics of different analogs of 11C-labeled TZTP for imaging muscarinic M2 receptors with PET

  • Alicia E. Reid

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • Corresponding Author InformationCorresponding author. Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA. Tel.: +1 631 344 4393; fax: +1 631 344 5815.
    • ,
  • Yu-Shin Ding

      Affiliations

    • Radiology Department, Yale University School of Medicine, New Haven, CT 06510, USA
    • ,
  • William C. Eckelman

      Affiliations

    • Molecular Tracer LLC, Bethesda, MD 20892, USA
    • ,
  • Jean Logan

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • David Alexoff

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Colleen Shea

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Youwen Xu

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Joanna S. Fowler

      Affiliations

    • Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA

Received 18 October 2007 ,Revised 3 January 2008 ,Accepted 6 January 2008.

References 

  1. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem. 1992;58:529–541
  2. Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A. Autoradiographic distribution of M1, M2, M3 and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse. 1997;26:341–350
  3. Quirion R, Aubert I, Labchak PA, Schaum RP, Teolis S, Gauthier S, et al. Muscarinic receptor subtypes in human neurodegenerative disorders; focus on Alzheimer's disease. Trends Pharmacol Sci. 1989;80–84
  4. Li M, Yasuda RP, Wall SJ, Wellstein A, Wolfe BB. Distribution of m2 muscarinic receptors in rat brain using antisera selective for M2 receptors. Mol Pharmacol. 1991;40:28–35
  5. Flyn DD, Mash DC. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2 and M3 muscarinic receptor subtypes in primate brain. Synapse. 1993;14:283–296
  6. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1:337–341
  7. Sauerberg P, Olesen PH, Nielsen S, Treppendahl S, Sheardown MJ, Honoré T, et al. Novel functional M1 selective muscarinic agonists. Synthesis structure-activity relationships of 3-(1,2,5-thiadiazoyl)-1,2,5,6-tetrahydro-1-methylpyridines. J Med Chem. 1992;35:2274–2283
  8. Knol R, Doornbos T, Bos J, Bruin K, Pfaffendorf M, Aanhaanen W, et al. Synthesis and evaluation of iodinated TZTP-derivatives as potential radioligands for imaging of muscarinic M2 receptors with SPET. Nucl Med Biol. 2004;31:111–123
  9. Kiesewetter DO, Carson RE, Jagoda EM, Herscovitch P, Eckelman WC. In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazoyl tetrahydropyridines. Synapse. 1999;31:29–40
  10. Farde L, Suhara T, Halldin C, Nyback H, Nakashima Y, et al. PET study of the M1-agonist [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. Dementia. 1996;7:187–195
  11. Carson RE, Kiesewetter DO, Jagoda EM, Der MG, Herscovitch P, Eckelman WC. Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab. 1998;18:1130–1142
  12. Kiesewetter DO, Lee J, Lang L, Park SG, Paik CH, Eckelman WC. Preparation of 18F-labeled muscarinic agonist with M2 selectivity. J Med Chem. 1995;38:5–8
  13. Jagoda EM, Kiesewetter DO, Shimoji K, Yamada M, Gomeza J, Wess J, et al. Regional brain uptake of the muscarinic ligand [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology. 2003;44:653–661
  14. Eckelman WC. The use of gene-manipulated mice in the validation of receptor binding radiotracer. Nucl Med Biol. 2003;30:851–860
  15. Podruchny TA, Connolly C, Bokde A, Herscovitch P, Eckelman WC, Kiesewetter DO, et al. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse. 2003;48:39–44
  16. Cohen RM, Podruchny TA, Bokde A, Carson RE, Herscovitch P, Kiesewetter DO, et al. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse. 2003;48(9):150–156
  17. Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry. 2006;63:741–747
  18. Benson BE, Carson RE, Kiesewetter DO, Herscovitch P, Eckelman WC, Post RM, et al. A potential cholinergic mechanism of procaine's limbic activation. Neuropsychopharmacology. 2004;29:1239–1250
  19. Perrin DD, Armarego WL. Purification of Laboratory Chemicals. 3rd ed.. New York: Pergamon Press Inc; 1988;
  20. Bell TW, Choi HJ, Harte W, Drew MG. Synthesis, conformatios and basicities of bicyclic triamines. J Am Chem Soc. 2003;125:12196–12210
  21. Yu KH, Park JH, Yang SD. Synthesis of [18F]fluorocholine analogues as a potential imaging agent for PET studies. Bull Korean Chem Soc. 2004;25(4):506–510
  22. Någren K, Müller L, Halldin C, Swahn C, Lehikonen P. Improved synthesis of some commonly used PET radioligands by the use of [11C]methyl triflate. Nucl Med Biol. 1995;22:235–239
  23. Wilson AA, Jin L, Garcia A, DaSilvain JN, Houle S. An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl Radiat Isot. 2001;54:203–208
  24. Ding YS, Lin KS, Garza V, Carter P, Alexoff D, Logan J, et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse. 2003;50:345–352
  25. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661–670
  26. Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A. Autoradiographic distribution of M1, M2, and M3 and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse. 1997;26:341–350
  27. Ravasi L, Kiesewetter DO, Shimoji K, Lucignani G, Eckelman WC. Why does the agonist [18F]FP-TZTP bind preferentially to the M2 muscarinic receptor?. Eur J Nucl Med Mol Imaging. 2006;33:292–300
  28. Ma Y, Kiesewetter DO, Jagoda EM, Huang BX, Eckelman WC. Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5- thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine, produced by human and rat hepatocytes. J Chromatogr B. 2002;766(2):319–329
  29. Gillespie TA, Lindsay TJ, Cornpropst D, Bonate PL, Skaggs TG, Delong AF, et al. Biological and biotechnological applications of ESI-MS, ACS symposium series. Am Chem Soc. 1996;619:315
  30. Murphy AT, Bonate PL, Kasper SC, Gillespie TA, Delong AF. Determination of xanomeline in human plasma by ionspray tandem mass-spectrometry. Biol Mass Spectrom. 1994;23:621–625
  31. Murphy AT, Kasper SC, Gillespie TA, Delong AF. Determination of xanomeline and active metabolite, N-desmethylxanomeline, in human plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B. 1995;668:273–280
  32. Shimoji K, Esaki T, Itoh Y, Ravasi L, Cook M, Jehle J, et al. Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow. Synapse. 2003;50:151–163

PII: S0969-8051(08)00008-5

doi: 10.1016/j.nucmedbio.2008.01.001

Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 287-298 , April 2008

Article Tools

* Image Usage & Resolution